Tumor Vaccines Articles & Analysis
9 news found
In addition, these new reagents can be applied in various fields, such as mRNA-base vaccine therapy for malignant tumors, protein replacement therapy, and gene editing using mRNA recombination technology. mRNA vaccines protect against infectious diseases like influenza, rabies, HIV and Zika virus infections. ...
Cancer Vaccine Development Based on pMHC Cancer vaccines to enhance the immune response, target tumor-specific mutations not present in normal tissues, and eradicate tumors. Vaccine Development Based on VLPs with MHC Complex To demonstrate and deliver specific tumor-associated MHC complex ...
At the completion of year two, the safety of the vaccine was assessed by an independent Data Safety Monitoring Board (DSMB), chaired by Dr. ...
ByCalviri
It is estimated that more than 240,000 cases of brain and nervous system tumors are diagnosed each year around the world. The most common and most lethal of these cancerous tumors are glioblastoma (GBM). ...
Abera is a biotechnology company with several proprietary vaccine platforms. The company has a vaccine candidate against pneumococcus that is being prepared for clinical phase evaluation and several pre-clinical vaccine candidates against other bacterial and viral infections. ...
The main goal of the vaccine is to elicit a strong and long-lasting immune response against tumor antigens by targeting class I and class II epitopes. ...
Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focusing on the development of cancer vaccines, announced today that it will use its proprietary recombinant overlapping peptide (ROP) technology to develop a new vaccine and diagnostic tests for Covid-19. The research will be carried out in collaboration with the renowned Nuffield Department of Medicine (NDM) at the University of ...
Calviri, Inc., a biotech startup spun out of Arizona State University Biodesign Institute, focused on prevention and treatment of cancer, announced results that demonstrate the potential of a prophylactic vaccine against cancer. The study of RNA processing errors in tumors highlighted that a large number of frameshift neoantigens are produced. ...
ByCalviri
OncoImmunity teams up with an innovative China based high-tech biotechnology company that has developed a dendritic cell-based vaccine delivery platform. The Chinese vaccine company is developing a personalized cancer vaccine solution with its platform that promises to deliver potent anti-tumor immune responses in ...